Scarica l'app Stockscreener
255.43
0.61%
1.56
Dopo l'orario di chiusura:
255.43
Precedente Chiudi:
$253.87
Aprire:
$254.79
Volume 24 ore:
771.84K
Relative Volume:
0.88
Capitalizzazione di mercato:
$16.05B
Reddito:
$4.44B
Utile/perdita netta:
$29.49M
Rapporto P/E:
-13,882.07
EPS:
-0.0184
Flusso di cassa netto:
$1.19B
1 W Prestazione:
+4.91%
1M Prestazione:
+11.05%
6M Prestazione:
+52.18%
1 anno Prestazione:
+116.04%
Intervallo 1D:
$252.09
$257.00
Intervallo di 1 settimana:
$242.11
$257.00
Portata 52W:
$105.00
$257.00
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
255.43 | 15.95B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Gold Stevie Award for Employer of the Year – Jazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals (JAZZ) Projected to Announce Earnings on Monday - MarketBeat
SummitTX Capital L.P. Reduces Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Castleark Management LLC Invests $9.21 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (JAZZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Cash Flow - TradingKey
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Cheap As Shares Jumped 115% - simplywall.st
Jazz Pharmaceuticals plc Revenue Breakdown – NASDAQ:JAZZ - TradingView
TAK Stock Price and Chart — NYSE:TAK - TradingView
Renaissance Technologies LLC Sells 17,400 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ|Jazz Pharmaceuticals PLC|Price:253.870|Chg%:-1.000 - TradingKey
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC - MarketBeat
Jazz Pharmaceuticals Reports Outcomes of 2026 Annual General Meeting with Strong Shareholder Backing - Kalkine Media
Jazz Pharmaceuticals held annual shareholder meeting in Dublin - Bitget
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling? - Yahoo Finance UK
Jazz Pharmaceuticals (NASDAQ: JAZZ) posts full 2026 AGM voting results - Stock Titan
Jazz Pharmaceuticals PLC $JAZZ is Systematic Financial Management LP's 5th Largest Position - MarketBeat
Jazz Pharmaceuticals PLC (JAZZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Globeflex Capital L P - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Position Boosted by California Public Employees Retirement System - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance UK
SEB Asset Management AB Purchases New Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 250.85 USD - Investing.com
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Principal Financial Group Inc. Increases Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals sets Aug. 3 webcast after market close - Stock Titan
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 - PR Newswire UK
Needham & Company LLC Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $282.00 - MarketBeat
JAZZ Maintains Buy Rating -- Price Target Raised to $282 by Need - GuruFocus
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Biotech Powerhouse with a 5.74% Upside Potential - DirectorsTalk Interviews
Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary - Quartr
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run - Yahoo Finance
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Upgraded by Canaccord Genuity Group - MarketBeat
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap? - Yahoo Finance
JAZZ Initiates Coverage On Canaccord Genuity -- Price Target Ann - GuruFocus
JAZZ Initiates Coverage On Canaccord Genuity -- Price Target Announces $290 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Illinois Municipal Retirement Fund Acquires 13,057 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ PHARMACEUTICALS PLC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $290 - Bitget
Hsbc Holdings PLC Purchases Shares of 5,035 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story? - simplywall.st
JAZZ Maintains Overweight Rating by Barclays -- Price Target Raised to $260 - GuruFocus
JAZZ Maintained by Wells Fargo -- Price Target Raised to $285 - GuruFocus
Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jazz Pharmaceuticals (JAZZ) Proxy filing Summary - Quartr
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):